Lymphoma: all 5,624 studies

Page 31 of 57. Open to participants first (824), then studies with results posted, then the rest; newest registration first within each.

• Maintenance Therapy Post-HSCT in High-risk Aggressive LymphomaStatus unknownNCT03695055Phase 2/3
• Study of Anti-CD22 CAR NK Cells in Relapsed and Refractory B Cell LymphomaStatus unknownNCT03692767Early Phase 1
• Long-term Outcome of AIDS-related Primary Central Nervous System Lymphoma Treated With High Dose Methotrexate and Combined Antiretroviral TherapyCompletedNCT03690895
• Study of Anti-CD19 CAR NK Cells in Relapsed and Refractory B Cell LymphomaStatus unknownNCT03690310Early Phase 1
• Intrathecal Rituximab With Standard Intrathecal Prophylaxis to Prevent CNS Relapse for CD 20+ Non Hodgkin LymphomaStatus unknownNCT03688451Phase 2
• A Safety and Tolerability Study of INCB053914 in Combination With INCB050465 in Diffuse Large B-Cell LymphomaCompletedNCT03688152Phase 1
• CD19-specific CAR T Cells With a Fully Human Binding Domain for CD19+ Leukemia or LymphomaActive, not recruitingNCT03684889Phase 1
• Study of TRPH-222 in Patients With Relapsed and/or Refractory B-Cell LymphomaCompletedNCT03682796Phase 1
• Indication to Transplant Patients With High Risk B Cells Lymphoma in Metabolic Complete Remission?Status unknownNCT03681938
• SMOLY : Phenotype and Functions of Monocyte Subtypes in High Grade B Lymphoma: Towards New Biomarkers?CompletedNCT03672682
• Allo-HSCT as First-line Consolidation in High-risk PTCLStatus unknownNCT03672084
• VT-EBV-N for Treatment of Severe in EBV Positive Extranodal NK/T Cell Lymphoma PatientsStatus unknownNCT03671850Phase 2
• A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin LymphomaActive, not recruitingNCT03671018Phase 1/2
• A Study to Compare the Efficacy and Safety of JHL1101 Versus Rituximab in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL)TerminatedNCT03670901Phase 3
• A Study to Compare the Bioequivalence and Safety of JHL1101 and Rituximab in CD20 Positive B Cell Lymphoma PatientsTerminatedNCT03670888Phase 1
• MB-CART20.1 LymphomaCompletedNCT03664635Phase 1/2
• Refractory Diffuse Large B-cell LymphomaCompletedNCT03664336
• Anti-PD-1 and Chemotherapy for R/R Hodgkin LymphomaCompletedNCT03664323
• Clinical Characteristics and Outcomes of Relapsed Follicular Lymphoma After Autologous Stem Cell Transplantation at Rituximab EraCompletedNCT03663894
• Study of GLS-010 Injection in the Treatment of Classical Hodgkin's LymphomaStatus unknownNCT03655483Phase 2
• A Study to Evaluate the Relationship of Lenalidomide With Tumor Flare Reaction and High Tumor Burden in Participants With Relapsed or Refractory Mantle Cell LymphomaCompletedNCT03647124
• AEDV Registry of Primary Cutaneous LymphomaStatus unknownNCT03646422
• Rituximab, Idelalisib, and Venetoclax in Relapsed/Refractory CLL/SLLWithdrawnNCT03639324Phase 1
• Clinical Trial in Chinese Patients of B-cell Non-Hodgkin's Lymphoma(GB226)Status unknownNCT03639181Phase 2
• Treatment of Newly Diagnosed Peripheral T-cell LymphomaStatus unknownNCT03631862Phase 4
• Maintenance Treatment of Chidamide in Stage IV or Relapsed/Refractory Extranodal NK/T-cell LymphomaStatus unknownNCT03630731Phase 2
• Study of Tisagenlecleucel in Combination With Pembrolizumab in r/r Diffuse Large B-cell Lymphoma PatientsCompletedNCT03630159Phase 1
• Efficacy and Safety of Chi-BEAC Combining With Auto-HSCT to Treat Aggressive Lymphoma SubjectsStatus unknownNCT03629873Phase 2
• SIMPLE Chemotherapy for NK Lymphoma/LeukaemiaStatus unknownNCT03623087Phase 3
• DA-EPOCH-R Induction Followed by Nivolumab Consolidation in Newly Diagnosed MYC, BCL2 and/or BCL6 Rearranged HGBLActive, not recruitingNCT03620578Phase 2
• Anlotinib for Advanced and Refractory Natural Killer /T-cell LymphomaCompletedNCT03618238Phase 2
• Avelumab in the Frontline Treatment of Advanced Classical Hodgkin Lymphoma - a Window StudyActive, not recruitingNCT03617666Phase 2
• Bortezomib in Combination With Ibrutinib in Ibrutinib Relapsed Mantle Cell LymphomaWithdrawnNCT03617484Phase 2
• The Efficacy of Salvage BGD With autoSCT Consolidation in Advanced Classical HL Patients Not Responding to ABVDCompletedNCT03615664Phase 2
• A Trial of Radiotherapy and Durvalumab in DLBCL and FLCompletedNCT03610061Phase 1
• Pembro + Blina Combination in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Leukemia or LymphomaWithdrawnNCT03605589Phase 1
• Prospective Study of the Prognostic Value of New Markers in Adults With ALK-positive Large Anaplastic LymphomaCompletedNCT03603847
• Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell TransplantationWithdrawnNCT03602898Phase 2
• Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCLActive, not recruitingNCT03602157Phase 1
• Chidamide Combined With Clad/Gem/Bu With AutoSCT in High Risk Hodgkin & Non-Hodgkin LymphomaStatus unknownNCT03602131Phase 2
• Pacritinib in Relapsed/Refractory Lymphoproliferative DisordersTerminatedNCT03601819Phase 1
• Study of Abexinostat in Patients With Relapsed or Refractory Follicular LymphomaActive, not recruitingNCT03600441Phase 2
• A Clinical Trial of Metformin in the Maintenance of Non-Hodgkin's Lymphoma PatientsStatus unknownNCT03600363Phase 2
• Tofacitinib Combined With Chidamide in R/R ENKTCLStatus unknownNCT03598959Phase 2
• Pesticide Associated Lymphomas: Expression of Treatment Resistance GenesCompletedNCT03597685
• A Study Evaluating the Safety of Cal-1 (LVsh5/C46) Drug Product in HIV-1 Infected Patient With High Risk LymphomaCompletedNCT03593187Phase 1/2
• A Single-center Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of LCAR-L10D Cell Formulations Targeting CD19 and CD22 in Patients With CD19- and/or CD22-Positive Relapsed/Refractory B-cell LymphomaTerminatedNCT03593109Phase 1
• Safety, Tolerability, and Pharmacokinetics of SHC014748M in Patients With Indolent B-Cell Hematologic MalignanciesStatus unknownNCT03588598Phase 1
• Pembrolizumab in Relapsed or Refractory Extranodal NK/T- Cell Lymphoma, Nasal Type and EBV-associated Diffuse Large B Cell LymphomasWithdrawnNCT03586024Phase 1/2
• A Pilot Investigator-Initiated Study of Ribavirin in Indolent Follicular Lymphoma and Mantle Cell LymphomaTerminatedNCT03585725Early Phase 1
• Role of [18F]-FDG Brain PET in Newly Diagnosed Primary Cerebral Lymphoma, in Immunocompetent Patient Older Than 60 YearsStatus unknownNCT03582254Not applicable
• Study Of Nivolumab Alone, Or In Combination With Vinblastin In Patients With Classical Hodgkin LymphomaCompletedNCT03580408Phase 2
• CAR.CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood NK Cells, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Participants With B-cell LymphomaWithdrawnNCT03579927Phase 1/2
• CD19-Specific T Cells Post AlloSCTTerminatedNCT03579888Phase 1
• A Clinical Trial of Decitabine in Relapse and Refractory Diffuse Large B Cell LymphomaStatus unknownNCT03579082Phase 4
• Rituximab Plus MG4101 Indolent CD20-positive Non-Hodgkin Lymphoma (NHL)TerminatedNCT03578198Phase 2
• The Clinical Research of Anti-CD20 CAR-T Cells in Patients With Refractory or Relapsed B Lymphocyte LymphomaStatus unknownNCT03576807Phase 1
• Trial of Idelalisib in Patients With Relapsed Diffuse Large B-cell LymphomaCompletedNCT03576443Phase 2
• BrEPEM-LH-22017 for Older Patients With Untreated Hodgkin Lymphoma (HL)Active, not recruitingNCT03576378Phase 1/2
• Study of Prognostic Factors in Adult Lymphoblastic LymphomaStatus unknownNCT03571997
• A Combination of Acalabrutinib With R-CHOP for Patient Diffuse Large B-cell Lymphoma (DLBCL)CompletedNCT03571308Phase 1/2
• Improving the Outcome of High-risk Aggressive B-cell Lymphoma Patients With Nivolumab Maintenance TherapyStatus unknownNCT03569696Phase 2
• Safety Profile of Idelalisib in Patients With Refractory Follicular LymphomaCompletedNCT03568929
• Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult T-LBL/ALLStatus unknownNCT03564704Phase 2/3
• Rituximab, Lenalidomide, and Nivolumab in Treating Participants With Relapsed or Refractory Non-Germinal Center Type Diffuse Large B Cell Lymphoma or Primary Central Nervous System LymphomaTerminatedNCT03558750Phase 1
• A Clinical Trial of Decitabine in Relapsed or Refractory T-lymphoblastic LymphomaStatus unknownNCT03558412Phase 4
• PLM60 for Peripheral T Cell Lymphoma (PTCL)WithdrawnNCT03553914Phase 1/2
• Efficacy and Safety of Decitabine Plus CHOP vs CHOP in Patients With Untreated Peripheral T-Cell LymphomaStatus unknownNCT03553537Phase 3
• Use of Venetoclax as Single Agent in Patients With Relapsed/Refractory BCL-2 Positive Peripheral T Cell LymphomaTerminatedNCT03552692Phase 2
• A Study to Determine Progression-free Survival (PFS) and Evaluate Participant Experience for Participants With Metastatic Anaplastic Lymphoma Kinase-positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) Treated With Anaplastic Lymphoma Kinase (ALK) InhibitorsCompletedNCT03546894
• Early Detection of Epstein-Barr Virus Related Disease.CompletedNCT03546101
• Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.Status unknownNCT03544723Phase 2
• PROCLAIM-CX-2029: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2029 for Patients With Solid Tumors or DLBCLCompletedNCT03543813Phase 1/2
• BV After Allogeneic Hematopoietic Stem Cell TransplantationStatus unknownNCT03540849Phase 2
• Cytoplasmic Activated PD-1 CAR T Cells in Refractory/Relapsed B Cell LymphomaStatus unknownNCT03540303Phase 1
• RCHOP Chemoimmunotherapy Preceded BY BBB Permeabilization by t-NGR Necrosis FactorCompletedNCT03536039Phase 2
• Elderly Hodgkin Lymphoma Patients Treated With ChemoradiotherapyStatus unknownNCT03535948
• A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple MyelomaTerminatedNCT03530683Phase 1
• Use of Optune TTF With Radiation as an Alternative for Elderly Patients With Primary CNS LymphomaWithdrawnNCT03530605Not applicable
• Assessment of Safety and Efficacy of IM19 for Relapsed or Refractory NHL PatientsStatus unknownNCT03528421Phase 1
• OPTmizing Advanced Stage HodgkIn LymphoMa patIentS TherapyStatus unknownNCT03527628Phase 2
• Platform Study for the Treatment of Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma (PRISM Study)CompletedNCT03527147Phase 1
• Study on the Role of FDG-PET in Patients With FL at Time of Relapse/ProgressionCompletedNCT03525665
• Haploidentical Stem Cell Transplant with Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLLCompletedNCT03524235Phase 1
• Treatment of Elderly Patients With Diffuse Large B-cell LymphomaStatus unknownNCT03513601Phase 4
• A Study of CS1001 in Subjects With Relapsed or Refractory Classical Hodgkin LymphomaCompletedNCT03505996Phase 2
• Venetoclax, Lenalidomide and Rituximab in Patients With Relapsed/Refractory Mantle Cell LymphomaStatus unknownNCT03505944Phase 1/2
• Testing the Combination of Copanlisib, Nivolumab and Ipilimumab in Patients With Advanced Cancer and LymphomaActive, not recruitingNCT03502733Phase 1
• Clinical Trial in Chinese Patients of Relapsed and Refractory Peripheral T Cell Lymphoma (GB226)Status unknownNCT03502629Phase 2
• Copanlisib Chinese PK StudyCompletedNCT03498430Phase 1
• Treatment of Refractory/Relapsed Non-Hodgkin Lymphoma With TriCAR-T_CD19Status unknownNCT03497533Phase 1/2
• Study on Tailored Treatment in Elderly Patients With Newly Diagnosed Primary Lymphoma of Central Nervous SystemCompletedNCT03495960Phase 2
• First Line Therapy of Advanced Stage Follicular Lymphoma in Patients < 60 Years Not Eligible fo Standard Immunochemotherapy and in All Patients ≥ 60 YearsCompletedNCT03492775Phase 2
• CAR-T Treatment for Relapse / Refractory Type Safety and Effectiveness of LymphomaStatus unknownNCT03488160Not applicable
• Bortezomib/Dexamethasone Therapy in Patients With Relapsed and/or Refractory Cutaneous T-cell LymphomaCompletedNCT03487133Phase 2
• RHCACD20MA (HS006) Combined With CHOP (Hi-CHOP) in Patients With Previously Untreated Diffuse Large B-cell LymphomaCompletedNCT03485118Phase 2
• A PhaseⅠb Study Evaluating Safety and Efficacy of C-CAR011 Treatment in B- NHL SubjectsCompletedNCT03483688Phase 1
• Abscopal Effect of Radiotherapy and Nivolumab in Relapsed Hodgkin Lymphoma After Anti-PD1 TherapyActive, not recruitingNCT03480334Phase 2
• Subclinical Cardio-toxicities Evaluation With Strain Rate Echocardiography After Chemotherapy and/or Mediastinal Radiotherapy in Patient With LymphomaCompletedNCT03480087
• R-BL-M-04 Versus R-(DA)-EPOCH and Autologous Stem Cells Transplantation in Patients With High-Grade B-cell Lymphoma Double-hit (HGBL DH) and High-Grade B-cell Lymphoma Not Otherwise Specified (HGBL NOS)Status unknownNCT03479918Phase 3

← Lymphoma overview